Intuitive Surgical director Gary Guthart sells $9.08M in stock

Gary Guthart, a director at Intuitive Surgical Inc. (NASDAQ:ISRG), sold 20,095 shares of common stock for a total value of approximately $9.08 million. The transactions, which occurred on October 23, 2026, were executed under a pre-arranged Rule 10b5-1 trading plan set to expire on June 15, 2027.

The shares were sold at prices ranging from $444.04 to $458.10 per share, with a weighted average sale price of $451.6117. Following these sales, Mr. Guthart directly holds 1,204,530 shares of Intuitive Surgical common stock. Additionally, shares are held indirectly through trusts for his daughter and son, each holding 26,247 shares.The insider sale comes as Intuitive Surgical trades at $450.08, near InvestingPro’s Fair Value estimate, with the company maintaining a market capitalization of $156 billion. The medical device maker has demonstrated strong momentum with 20% revenue growth, though it trades at a P/E ratio of 54.16. According to InvestingPro data, 21 analysts have recently revised their earnings upwards, suggesting continued confidence in the company’s prospects despite the insider transaction.

In other recent news, Intuitive Surgical reported third-quarter revenue of $3.05 billion, surpassing both Oppenheimer’s estimate of $2.92 billion and consensus expectations of $2.91 billion. However, GAAP earnings per share were $1.49, which fell short of Oppenheimer’s $2.38 estimate and the consensus of $2.39, due to a $450 million litigation settlement. The company’s procedure growth remained a focal point, with Truist Securities highlighting a significant 40% increase in net da Vinci placements during the third quarter. Stifel also acknowledged the company’s performance, maintaining a Buy rating and a $550 price target after Intuitive Surgical exceeded consensus revenue and earnings projections.

Despite these positive developments, RBC Capital lowered its price target to $550 from $575, citing concerns about U.S. volume headwinds. Mizuho also reduced its price target to $400 from $415, although they noted the company’s strong performance across its Systems, Services, and Instruments & Accessories segments. Truist Securities reiterated a Buy rating with a $510 target, emphasizing the robust demand for capital and the growth in Xi and X installations. Oppenheimer maintained an Outperform rating with a $500 target following the earnings report. These recent developments indicate varied analyst perspectives on Intuitive Surgical’s future performance.